Can research agents deliver reproducible net research gain The TRACE-Med framework for clinical research

The challenge facing medical research is not only information overload but also the disconnects among evidence, questions, research, implementation, and replication. Research agents can call external tools, integrate multi-source information, and perform multistep tasks, but they may likewise amplify fabricated citations, confirmation bias, version drift, and unauthorized actions into systemic research errors. Existing evaluations of medical artificial intelligence have mostly focused on simulated tasks, and rigorously defined agents remain understudied; there is also a lack of unified definitions, comparable endpoints, and prospective validation pathways for treating research agents as complex research interventions. Accordingly, this article proposes a falsifiable proposition: research agents should be evaluated under prespecified research quality standards by whether they increase reproducible net research benefit without increasing the risk of serious research errors. TRACE-Med organizes the workflow into five stages—Track (evidence tracing), Refine (question refinement), Architect (research architecting), Coordinate (coordinated implementation), and Evaluate (validation and replication)—and uses evidence provenance, prespecification, separation of privileges, and independent reruns as putative mechanisms of action. Clinical implications: This article positions the minimum implementable research unit, Valid and Reproducible Research Gain (VRRG), and Agent-Induced Research Error Rate (AIRER) as candidate components for future evaluation of the implementation effects of research agents, rather than as validated scales or efficacy endpoints. Current evidence supports controlled augmentation, not unsupervised replacement; next steps should employ blinded outcome adjudication, randomized or crossover task designs, multicenter implementation studies, and independent replication to test whether the framework produces net benefit.

Key Words: research agents; clinical research; reproducibility; artificial intelligence governance; open science; TRACE-Med